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Review
Application of Fluorescence-Guided
Surgery to Subsurface Cancers Requiring
Wide Local Excision: Literature Review
and Novel Developments Toward Indirect
Visualization
Kimberley S. Samkoe, PhD1,2,3, Brent D. Bates, MS2, Jonathan T. Elliott, PhD3,
Ethan LaRochelle, BE3, Jason R. Gunn, BS3, Kayla Marra, BS3,
Joachim Feldwisch, PhD4, Dipak B. Ramkumar, MD, MS5, David F. Bauer, MD1,
Keith D. Paulsen, PhD3, Brian W. Pogue, PhD3, and Eric R. Henderson, MD5,6
Abstract
The excision of tumors by wide local excision is challenging because the mass must be removed entirely without ever viewing it
directly. Positive margin rates in sarcoma resection remain in the range of 20% to 35% and are associated with increased
recurrence and decreased survival. Fluorescence-guided surgery (FGS) may improve surgical accuracy and has been utilized in
other surgical specialties. ABY-029, an anti-epidermal growth factor receptor Affibody molecule covalently bound to the near-
infrared fluorophore IRDye 800CW, is an excellent candidate for future FGS applications in sarcoma resection; however,
conventional methods with direct surface tumor visualization are not immediately applicable. A novel technique involving imaging
through a margin of normal tissue is needed. We review the past and present applications of FGS and present a novel concept of
indirect FGS for visualizing tumor through a margin of normal tissue and aiding in excising the entire lesion as a single, complete
mass with tumor-free margins.
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Introduction
Application of fluorescence guidance to sarcoma and other
subsurface cancers that require negative margins for cure is
possible in theory; however, it requires that the cancer’s loca-
tion be monitored indirectly, through its surrounding tissues.
Advances such as the clinical development and implementation
of near-infrared fluorophores for surgical guidance has allowed
for deeper visualization of target tissue due to increased light
penetration and reduced tissue autofluorescence; however, the
requirement for indirect tumor visualization introduces addi-
tional barriers to use of current technology. A recent review by
Tipirneni et al highlights the current clinical trials investigating
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fluorescence-guided surgery (FGS) for the resection of a vari-
ety of cancer types.1 Our research group has undertaken foun-
dational research using a sarcoma-based model through which
we hope to define new methodologies to facilitate indirect
visualization of subsurface cancers. Here, we outline wide
local excision surgery for cancer resection, summarize the
development of direct visualization fluorescence techniques,
review modern applications of FGS using targeted probes for
cancer visualization, and describe our early investigation of
indirect tumor visualization utilizing near-infrared fluores-
cence (NIRF).
Fluorescence Guidance and Wide Local
Excision Surgery for Cancer Resection
The goal in surgery is to effect improvement of the patient’s
health through a physical intervention that accomplishes one
or more of the following: (1) alteration of dysfunctional
anatomy, (2) implantation of a device, and (3) removal of
an aberrant, harmful structure or tissue. Successful surgery
therefore requires the surgeon to correctly distinguish the
various tissue types encountered during the operation and
to intervene only on the target tissues, leaving the others
intact and preferably untouched. This result is not always
achieved easily, and numerous technological enhancements
to normal surgery have been proposed, one of which is the
use of fluorescence guidance.
Fluorescence-guided surgery has proven particularly use-
ful in the removal of brain,2-5 bladder,6-8 and head and neck
cancers,9,10 where the tumor is generally present at the
organ’s surface. These tumors can be visualized directly using
fluorescence and can be simultaneously removed in a piece-
meal or bulk fashion (Figure 1A-C). However, the application
of current fluorescence technology to many other cancers,
such as sarcoma, is prevented due to the requirements for
complete resection without direct visualization of the mass
(Figure 1D-F).
Curative surgery for many cancers requires that the tumor be
removed with a zone of normal tissue, called the margin, sur-
rounding the tumor. This is referred to as wide local excision. A
tumor removed with no exposed cancer is said to have a
“negative margin,” while the presence of cancer at the surface
of the excised tumor is deemed a “positive margin.” Sarcomas,
cancers derived from mesoderm—the middle germ layer, are
one cancer type that generally requires negative margins for
surgical cure. Although a difficult feat with tumors present at
an organ’s surface, ensuring a negative margin in sarcoma
resection is complicated by the subsurface nature of these
masses, requiring surgeons to accurately estimate the precise
location and distance of the tumor surface from their dissection
without directly visualizing the mass. This is not always
achieved easily and frequently results in positive margins,
which are associated with increased local recurrence and lower
survival rates.11-14 Unfortunately, resection of sarcoma tumors
results in positive margins in approximately 22% to 34% of
cases, as reported in three large series.11-13
Fluorescence guidance during wide local excision of sar-
coma tumors is a strong candidate for future applications and
may improve primary resection of other subsurface tumors.
However, there is clinical need for a novel technique to allow
surgeons to visualize and monitor tumor through a margin of
normal tissue.
Historical Overview of FGS
Given the importance of surgical margins in predicting recur-
rence and outcome in many solid tumors, the idea that fluor-
escence can be used for in situ tumor differentiation has
captivated clinicians and researchers alike. Although early
reports of in vivo fluorescence use dates to at least 1948, when
Moore et al reported the use of fluorescein sodium (FS) as a
Figure 1. A, Concept of direct fluorescence-guided surgery (FGS),
in which the tumor is present at the organ’s surface and can be
visualized directly using an intraoperative fluorescence microscope.
B, Anticipated resection of a glioma tumor as seen on brain mag-
netic resonance imaging (MRI; dashed yellow line). C, Intraopera-
tive view of a glioma tumor as seen with direct fluorescence
visualization after administration of 5-aminolevulinic acid (ALA).
D, Concept of indirect FGS, in which fluorescence is utilized to
display tumor location and depth through a margin of normal
tissue. E, Anticipated resection of a soft-tissue sarcoma on com-
puted tomography (CT; dashed yellow line). F, Intraoperative
photograph of a soft-tissue sarcoma that has been removed with
a margin of muscular tissue surrounding the tumor.
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tool for surgical resection of brain tumors,15 intraoperative
techniques have only gained wider adoption since the 1990s.
Analogous to FS, indocyanine green (ICG), which originated in
ophthalmology for retinal angiography, has also been utilized
as a vascular tracer in neurosurgery. Both of these agents are
readily available, and widespread adoption can be attributed
mainly to their status as approved Food and Drug Administra-
tion (FDA) drugs that are then used off-label for FGS. As
vascular tracers, FS and ICG extravasate in brain regions where
the blood–brain barrier is compromised, allowing for the dis-
crimination of tumor tissue over normal tissue. However, a
major limitation of these tracers is that they rely exclusively
on the enhanced permeability and retention (EPR) effect as the
driver of contrast. Due to their affinity to bind to albumin, they
have an effective molecular weight of >100 kDa and thus
remain primarily in the blood. As a result, in regions of the
infiltration margin where blood–brain barrier disruption has not
yet occurred, tumor contrast is limited and variable, ultimately
reducing the efficacy of these agents. Nevertheless, they have
been adopted for use in lung, head and neck, breast, colorectal,
melanoma, gastric, endometrial, and prostate cancer resections,
and there are currently 54 active and recruiting studies listed on
ClinicalTrials.gov using these two agents.
Due to the enormous costs of drug development, FGS
would continue to be limited to off-label use of already
approved agents. In 1999, the FDA approved the use of
5-aminolevulinic acid (ALA) for the treatment of actinic ker-
atosis by photodynamic therapy. Because ALA also induces the
accumulation of protoporphyrin IX (PpIX) in certain tumor
cells (due to its naturally occurring presence as a precursor to
PpIX in the heme synthesis pathway), Stummer et al were able
to demonstrate its use as a highly specific marker of high-grade
glioma tissue.2 Their seminal paper in Lancet Oncology in
2006 showed an improvement in the number of patients with
6-month progression-free survival (from 21% to 41%) with
the use of ALA during glioma surgery.2 Subsequent papers
by groups at the University of Toronto and Dartmouth
College3,16,17 have refined the broad strokes of Stummer
et al, characterizing the use of ALA in low-grade gliomas and
other brain tumors, as well as advancing mechanistic under-
standing through preclinical research.
Although the surgical use of ALA continues to be investi-
gated in at least 50 studies listed on ClinicalTrials.gov, it is
generally understood that for brain tumors, ALA provides
excellent visual contrast in high-grade gliomas, but low-
grade gliomas require quantitative imaging or sensing tech-
niques to differentiate between normal and diseased tissues.3,17
It is likely that both reduced EPR and reduced downregulation
of ferrochelatase associated with low-grade or marginal glioma
cells contribute to the reduced sensitivity of ALA in these
cases. Furthermore, anecdotal evidence from Dartmouth’s
experience, corroborated by preclinical results,18 suggest that
ALA can enhance normal tissue in certain cases and that con-
current therapies such as dexamethasone can influence the
degree of background enhancement associated with ALA.
These observations limit the applicability of ALA and have
resulted in further exploration of imaging agents for use
in FGS.
In recent years, there has been a strong push by a number of
groups to develop more specific tumor-enhancing fluorescent
agents to overcome certain limitations of current agents, which
are mainly limited to FS, ICG, ALA, and methylene blue.
Neurosurgical applications represent the knife-edge of transla-
tional development, but applications in head and neck surgery
have also introduced new agents in the past 5 years. Although
drug development costs remain an obstacle, the introduction of
good manufacturing practice (GMP)-produced near-infrared
fluorophore IRDye 800CW (LI-COR Biosciences, Inc, Lin-
coln, Nebraska),19 as well as microdose exploratory investiga-
tional new drug (eIND) pipelines by Dartmouth20,21 and other
groups, has spurred development. In the next section, we will
review the targeted agents that have been developed in the last
5 years for FGS applications and highlight the ongoing and
future clinical trials at Dartmouth College.
Modern Applications of NIRF for Targeted
Probe Surgical Guidance for Cancer
Neurosurgery
Intraoperative ALA continues to be the most important tool
for high-grade glioma resection guidance and is standard of
care for several European countries.4 In terms of clinical
acceptance, there is level I evidence showing the efficacy in
World Health Organization III and IV grade gliomas. Perhaps
more importantly, ALA has been readily adopted by surgeons
because it is specific and sensitive within the context of
high-grade gliomas and can be visualized directly using an
operating microscope equipped with standard filters.
Fluorescence-guided surgery research and development have
centered on expanding the types of tumors for which detect-
able contrast can be measured and, pursuant to that, improv-
ing the means of detection over direct visualization.
Pioneering work at the University of Toronto and Dartmouth
College has refined probe-based and quantitative wide-field
imaging systems,3,16,17 to the point where 0.01 (17.8 nM) and
0.1 mg/mL (178 nM) concentrations, respectively, can be
readily detected. As device sensitivity increases, tumor
enhancement becomes more detectable, while background
enhancement (false positive) is readily reduced.
BLZ-100, a synthetic peptide ICG derivative conjugate
(Blaze Bioscience, Seattle, Washington), was the first targeted
fluorophore to enter phase 1 clinical trials.5,22 The conjugate is
a 36-amino acid sequence isolated from the venom of the
scorpion, Leiurus quinquestriatus, and has demonstrated
tumor-specific activity mainly through annexin A2 binding.
The clinical motivation for BLZ-100 development has been
pediatric brain cancer, although the company has completed
proof of principle and preclinical studies examining several
types of cancer including pediatric glioma, head and neck,
sarcoma, breast, and skin cancer. BLZ-100 has demonstrated
strong contrast in preclinical studies between tumor and normal
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tissue, and toxicology studies have been completed in rats and
monkeys with promising results.5,23 Clinical trials to determine
the efficacy of BLZ-100 are currently underway for several
cancer types.
A 2013 study by Sexton et al compared IRDye-labeled
cetuximab and IRDye-labeled anti-epidermal growth factor
receptor (anti-EGFR) Affibody molecules (Affibody AB,
Solna, Sweden) and found that the smaller Affibody-based
dyes penetrated through the blood–brain barrier and provided
better enhancement in the peripheral tissue.24 This finding led
the researchers to develop a GMP production pipeline to man-
ufacture a compound consisting of IRDye 800CW conjugated
to synthetic anti-EGFR Affibody, subsequently called ABY-
029, for preclinical toxicology and efficacy studies, followed
by a first in-human clinical trial (NCT0291925).20,21 The pipe-
line crystallized around the idea that microdoses of synthetic
peptide conjugate could be administered to patients under an
eIND, avoiding the need for multispecies toxicology studies.
Consequently, for successful imaging of microdose-level (30
nanomoles) fluorescence, there were several requirements:
(1) the receptor of interest must be expressed in abundance,
(2) the fluorophore must be excited by a powerful wide-field
light source at close to peak absorption wavelength, and (3) the
remitted signal must be detected by a sensitive, cooled scien-
tific complementary metal-oxide semiconductor (CMOS) cam-
era.25 Other considerations included the need for highly
specific binding with low background signal and fast plasma
clearance to allow imaging 1 to 4 hours postinjection with good
contrast. In 2016, Samkoe et al published toxicology results for
ABY-029 with an absence of significant adverse effects at
1000 the microdose level,20 and in a subsequent study, favor-
able contrast ratios were identified at early imaging time points
(1-48 hours).26 Furthermore, simultaneous injection of ABY-
029, PpIX, and low-molecular-weight IRDye 680RD-CX (LI-
COR Biosciences, Inc) showed that for EGFR-positive tumors,
ABY-029 had higher tumor contrast than PpIX or perfusion
dye (IRDye 680RD-CX) and that combining ABY-029 and
PpIX information provided better discrimination between
tumor and normal brain than either alone. Interestingly, the
efficacy of this dual tracer method was found in both EGFR-
positive and EGFR-negative tumors.27 ABY-029 is currently
being investigated in a first in-human clinical trial, and addi-
tional preclinical work is underway to further investigate the
potential application of this molecule toward brain and other
types of cancer.
Head and Neck Surgery
Successful surgical resection of head and neck squamous cell
carcinomas (HNSCC) depends on a careful balance between
obtaining clear surgical margins and maintaining physiological
function and cosmetic appearance of pertinent structures in the
facial region and oral cavity. The current clinical standard of
care for HNSCC margin determination is gross palpation dur-
ing surgery and confirmation of clear margins with pathologi-
cal tissue staining; however, microscopic tumor burden at or
near the surgical margins remains high and recurrence of these
patients approaches 40%.28 Several studies involving ICG have
been undertaken for the detection of tumor margin boundaries
and sentinel lymph node detection. Indocyanine green is a
nonspecific perfusion fluorophore and, as such, determination
of tumor boundaries depends on the differential uptake and
clearance kinetics in normal and diseased tissues, ultimately
resulting in poor tissue delineation.10 However, ICG plays a
much more promising role in the detection of sentinel lymph
nodes, where passive uptake and retention are a feature of
pathological lymph node detection, and the near-infrared
detectability lends to deeper node imaging.10
Recently, fluorescently labeled molecular targeting agents
for HNSCC resection have gained momentum to better target
tumor versus normal tissue and to visualize both bulk and
microscopic tumor burden. The Rosenthal group has pioneered
work in near-infrared imaging of EGFR-targeted antibo-
dies.9,29-35 Cetuximab and panitumumab have both been inde-
pendently conjugated with IRDye 800CW and are in active
clinical trials (NCT01987375 and NCT02415881, respectively)
for HNSCC detection and surgical removal. However, at short
time periods, antibody-based imaging agents generally had
confounding signal in normal tissues resulting in low tumor-
to-background ratios (TBRs) or tissue contrast. To overcome
this limitation, extensive clearance times (>48 hours) are used,
where internalization and cell cycling dominate the signal but
provides promising TBRs approaching 5:1.9,35 To further
increase TBRs, simultaneous injection of unlabeled cetuximab
much larger than the fluorescent dose (a “cold-dose”) is being
tested to overwhelm endogenous EGFR sinks and increase the
observed contrast by maintaining higher levels of circulating
fluorescent antibody.35
The recent development of GMP-produced IRDye-labeled
anti-EGFR Affibody molecule, ABY-029, has spurred interest
in head and neck surgery. A clinical trial of ABY-029 in
HNSCC resection was recently approved at our institution
(NCT03282461), and it is possible that this Affibody com-
pound may represent a superior alternative to the larger
antibody-based compounds cetuximab and panitumumab.
However, improvement in long-term survival will be deter-
mined from the ongoing and future clinical trials, and further
investigation is likely required to delineate the optimal tech-
nique for fluorescence-guided HNSCC resection.
Orthopedic Surgery
Fluorescence applications in orthopedic surgery are less
developed than in many other medical disciplines. One reason
for slower progress stems from the fact that the most common
tissue target for orthopedic surgeons, bone, is generally char-
acterized well with conventional radiographs, which can be
employed on-demand during surgery. Other imaging modal-
ities such as computed tomography (CT) and magnetic reso-
nance imaging (MRI) are also readily available and can
provide detailed and reliable anatomical data. A second rea-
son is that the rigidity of bone provides an unambiguous
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tactile reference point with landmarks that are consistent
across patients. Finally, orthopedic operations for cancer, the
greatest impetus for molecular guidance in other surgical spe-
cialties, comprise an exceptionally small proportion of all
orthopedic procedures. Still, molecular-guided fluorescence
imaging is being explored increasingly in orthopedics, espe-
cially with reference to surgical removal of primary bone and
soft-tissue sarcomas.
The area of most study for orthopedic oncologic fluores-
cence applications is the detection of residual cancer cells at
the time of primary tumor resection. In 2012, Mito et al
published an important manuscript detailing the successful
use of a cathepsin-activated fluorescent probe for detection
of residual cancer cells following the removal of soft-tissue
sarcomas in a mouse model.36 Detection of residual disease
had a positive association with disease recurrence, and the
authors were able to demonstrate reduced local recurrence
with real-time fluorescence-guided removal of residual
tumor cells. The same group later published a first-in-
human phase 1 clinical trial (NCT01626066) using a
protease-activated fluorescent probe (LUM015; Lumicell
Inc, Wellesley, Massachusetts) and demonstrated safe
administration and tumor-specific labeling in soft tissue
sarcomas.37 A second group recently published a series of
studies demonstrating that the use of a telomerase-
dependent adenovirus fluorescent probe (OBP-401; Oncolys
BioPharma Inc, Tokyo, Japan) during surgery improves
tumor resection, reduces local recurrence, and improves
disease-free survival in murine models of osteosarcoma,
retroperitoneal fibrosarcoma, and soft tissue sarcoma.38-41
These data indicate the potential clinical utility of FGS in
reducing recurrence rates of certain musculoskeletal tumors.
Similar to prior work in neurosurgery and otolaryngology,
the work of these two groups relies on direct, superficial rec-
ognition of cancer cells.36-41 Although real-time detection of
residual cancer cells offers an immense improvement over cur-
rent surgical methods, avoiding residual cancer altogether
would be more desirable. However, for reliable wide local
excision with negative margins, definition of new fluorescence
applications will be required in order to transition to indirect
tumor visualization through marginal tissues. Here, we intro-
duce the foundational fluorescence work required to develop
indirect FGS using a sarcoma model. Furthermore, we have
initiated a phase 0 clinical trial investigating ABY-029 in pri-
mary sarcoma tumors (NCT03154411).




Curative surgery for sarcoma requires that the tumor be
removed with a margin of normal tissue surrounding the
lesion. However, accurate localization of a cancer through its
surrounding tissues and estimation of margin thickness will
require a model that accommodates for numerous factors.
These include: (1) energy of the excitatory signal, (2) tumor
volume, (3) tumor fluorophore uptake, (4) tumor optical char-
acteristics, (5) surrounding tissue thickness before dissection,
(6) surrounding tissue fluorophore uptake, (7) surrounding
tissue type(s) and optical characteristics, and (8) presence and
effects of preoperative cancer therapies on the tumor and
surrounding tissue optical properties. These important factors
are knowable prior to surgery through the use of three-
dimensional imaging (MRI and/or CT) and analysis of the
tumor’s optical properties at the time of diagnostic biopsy. This
would require the intended fluorescent probe to be administered
at the time of biopsy so that the tumor’s probe uptake could be
assessed. The near-infrared EGFR-targeted probe ABY-029 is
an excellent candidate as the excretion kinetics are fast, and
preliminary work suggests that optimal TBR contrast occurs
within hours, compared to days as in the case of antibody-
conjugated molecules.26 In addition, tissue autofluorescence is
minimized in the near-infrared region, further enhancing tumor
contrast and facilitating accurate indirect tumor visualization.
Finally, the GMP form of ABY-029 has been rigorously tested
for toxicity20 and as a targeted agent in paired-agent imaging of
several EGFR-expressing cancers42-44 and is currently approved
for human testing through the FDA eIND #122681.
Because the development of a surgical model requires
reproducible working conditions for numerous serial experi-
ments, we chose to begin delineating these optical properties
in a tissue-simulating phantom model45 using well-described
scattering and absorption parameters.46,47 We then transitioned
our work to a naive rodent model for in vivo validation in
normal tissues. Finally, we tested the ability of a surgeon,
blinded to the location of a tumor-simulating inclusion, to suc-
cessfully isolate the inclusion with *1 cm margins using a
preclinical surgical imaging system.
Materials and Methods
Well Phantoms
Molds were created by drilling holes with 5 mL volume
(19 mm diameter, 17 mm depth) into black Delrin® plastic.
Powder gelatin (10% wt/vol) was mixed in hot water, stirred
vigorously until cooled to 30C, and infused with 50 nM of
IRDye 800CW. Varying concentrations of blood and intralipid
were added to the gelatin mixture, and then the mixtures were
poured into the appropriate wells. The rows had varying blood
concentrations (0.5%, 1%, and 2% vol/vol) as an absorbing
agent, and the columns had varying intralipid concentrations
(0.5% and 1% vol/vol) as a scattering agent. The phantoms
were cooled overnight at 4C, and then imaged on a Solaris
preclinical surgical imaging system (PerkinElmer, Inc, Wal-
tham, Massachusetts) using the 750 nm channel. Regions of
interest (ROIs) were created to encompass the center region of
the well, and the average fluorescence intensity per pixel was
determined in Fiji software (ImageJ v1.51j),48-50 then normal-
ized to the highest muscle value (1% intralipid, 2% blood).
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Naive Mouse Study
All procedures were performed in accordance with protocols
and standard operating procedures approved by the Institu-
tional Animal Care and Use Committee at Dartmouth College.
Female nude mice (6 weeks old, Charles River Laboratories,
Inc, Wilmington, Massachusetts) were placed on a chlorophyll-
free diet (Purified Mouse Diet; MP Biomedicals, LLC, Illkirch,
France) for a minimum of three days in order to reduce the
effects of autofluorescence. Previous studies, as well as unpub-
lished data from our laboratory, have confirmed binding of
ABY-029, an anti-EGFR Affibody-IRDye 800CW conjugate,
to murine EGFR.51,52 A 1:1 mixture of ABY-029 and IRDye
700DX carboxylate, the latter acting as a nonspecific perfusion
agent to control for any observed EGFR binding in these nor-
mal tissues, was injected (4.98 mM, 200 mL) into the tail vein
under light isoflurane anesthesia (1%-2% isoflurane, 1 L/min
O2). At 1- and 2-hour time points, mice were anesthetized and
then killed by cervical dislocation followed by diaphragmatic
puncture. Tissue was removed from the right and left flanks of
2 mice at both the 1- and 2-hour time points (n ¼ 4, per time
point). Right and left flanks from an additional control mouse
(n ¼ 2) were processed in a similar manner but did not receive
injection of the fluorescent agents. Muscle, fascia, sciatic
nerve, and fat were excised from each flank and utilized for
ex vivo fluorescence analysis. The tissues were placed on a
glass slide and imaged on three preclinical fluorescence sys-
tems: (1) Solaris (PerkinElmer)—a broad-beam, open-air sur-
gical system, (2) Pearl (LI-COR Biosciences, Inc)—a broad-
beam, black box system, and (3) Odyssey (LI-COR Bios-
ciences, Inc)—a black box, flatbed scanning system. Ex vivo
fluorescence data were analyzed using Fiji48-50 by creating
ROIs around the tissues of interest in each of the images pro-
duced by the Solaris, Pearl, and Odyssey imaging systems.
Fluorescence signal was normalized to the muscle tissue for
each time point and imaging system. Muscle was used as a
reference tissue because it is known to be devoid of EGFR.
In the absence of EGFR, ABY-029, and IRDye 700DX, car-
boxylate should demonstrate identical pharmacokinetics, thus
normalizing fluorescence signal between imaging systems,
time points, and tissue types. This method has previously been
used successfully as a control for ABY-029 and other EGFR-
targeted imaging agents.42-44
Surgical Phantoms
Large cylindrical phantoms (11 cm diameter, 6 cm height) were
created with a 16.4 cm3 tumor-simulating inclusion at approx-
imately 2 cm depth. Both the inclusion and background phan-
toms were made with 1% (vol/vol) blood and 1% (vol/vol)
intralipid to best represent general connective tissue. First, in
order to test the inclusion fluorescence, ABY-029 concentra-
tion was varied (125, 500, and 1000 ng/mL) while the back-
ground tissue remained free of fluorophore. Second, the TBR
was studied by holding the ABY-029 concentration in the
inclusion at 500 ng/mL and varying the background
concentration (50, 100, 166.7, 250, and 500 ng/mL) such that
the effective TBR would be 10:1, 5:1, 3:1, 2:1, and 1:1, respec-
tively. A blinded orthopedic oncology surgeon then attempted
to locate each inclusion by using a Solaris imager to display
fluorescence intensity over the surface of the phantom. Using
prior knowledge of the inclusion volume, surgical cuts were
made to the phantom, beginning on the outermost aspects and
progressing inwards, in order to decrease the tissue-mimicking
margins to approximately 1 cm. The stopping criteria were
(1) an expected volume of the phantom was left (16.4 cm3 þ
1 cm margins), with fairly even fluorescence signal on all
six sides, or (2) the inclusion was cut into. If a surgical incision
was made into the inclusion, this was considered a failed
experiment, and no margin thickness was recorded. The
remaining cuboid was cut horizontally and vertically through
the center and each section imaged next to a ruler. The margin
thickness was analyzed using Fiji software48-50 and plotted
against mean fluorescence for the varying inclusion ABY-
029 concentrations and TBRs.
Results and Discussion
The presence of light absorbing and scattering agents in a
medium or tissue can greatly affect the observed emission
intensity of a given fluorophore. Although these effects are
reduced in the near-infrared region, as compared to the visible
wavelengths, they are not negligible. Here, we tested the effects
Figure 2. Gelatin phantoms demonstrate the effects of normal con-
nective tissue optical properties on ABY-029 fluorescence. Each well
held a constant concentration of ABY-029 (50 nM). The concentration
of blood was varied in the rows, and the concentration of intralipid
was varied in the columns. The wells with the optical properties best
representing general connective tissue, fat, and muscle are shown.45-47
The value in the center of each well is the average fluorescence nor-
malized to the muscle values best represented by mouse muscle (1%
intralipid, 2% blood).
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of light-absorbing (blood; 0.5%, 1%, and 2%) and scattering
(intralipid; 0.5% and 1%) media in biologically relevant con-
centrations on the observed fluorescence of a constant ABY-
029 concentration (50 nM).45-47 As demonstrated in Figure 2,
ABY-029 fluorescence increases proportionally with scattering
agents and decreases proportionally with absorbing agents.
Since muscle and fat are the most common normal tissues to
be associated with soft-tissue sarcomas, the range of absorbing
and scattering parameters of these tissues45-47 is highlighted.
The simulation accuracy of these tissue-mimicking phan-
toms was tested by administering ABY-029 to naive mice and
observing effective fluorescence intensities in normal tissues at
1 and 2 hours postadministration. Normalized fluorescence
values for each fluorescence system can be observed in Figure
3. In general, tissues from the control mouse all had similar
autofluorescence signal to the muscle tissue. In the experimen-
tal mice, there were no differences observed between ABY-029
and IRDye 700DX carboxylate for each imaging system, time
point, and tissue type, indicating that ABY-029 binding to
native EGFR in these naive tissues was not contributing to the
accumulation or retention of the targeted agent. These data
suggest that the EGFR-targeted fluorophore ABY-029 may
be utilized to preferentially visualize EGFR-positive sarcoma
tumors over the surrounding naive tissues. The exception to
this was in the nerve tissue of the control mouse when scanned
on the Odyssey, where the fluorescence signal in the 700-nm
channel was over 2x that in the 800-nm channel. However, this
effect of autofluorescence and control nerve variance was only
observed in the Odyssey, and therefore, these effects are likely
artifacts of the surface-weighted imaging in this system and a
result of having only a single set of control tissues. Such effects
were not observed in the Solaris or Pearl systems and thus
would not affect fluorescence signal in the clinical context.
Investigation is currently underway in our laboratory to evalu-
ate the ability of ABY-029 to label EGFR-positive sarcoma
tumors in a murine model.
Comparing ABY-029 fluorescence in gelatin phantoms
(Figure 2) to that of naive mice connective tissues (Figure 3)
indicates that the phantoms accurately represent the range of
fluorescence that will be observed in normal tissues. At short
time periods (1 hour), the fluorescence intensity of ABY-029 in
normal mouse fat, fascia, and nerve varied from 0.3 to 2 that
of muscle. The gelatin phantoms displayed maximal contrast
ratios of 0.6 to 1.6 that of the muscle condition with the
Figure 3. A, Uptake of ABY-029 and IRDye 700DX in ex vivo naive mouse tissues. Images are nonnormalized to demonstrate the different
optical properties of the fluorophores. Fluorescence intensity, normalized to muscle, is compared for three imaging systems: (B) Solaris
(PerkinElmer)—broad beam, open-air (660 and 750 nm channels), (C) Pearl (LI-COR Biosciences, Inc)—broad beam, closed box (700 and 800
nm channels), and (D) Odyssey (LI-COR Biosciences, Inc)—flatbed, scanning (700 and 800 nm channels). In general, control tissues demon-
strated similar autofluorescence to muscle tissue. No differences were observed between the epidermal growth factor receptor (EGFR)-
targeted fluorophore ABY-029 (800 nm channel) and the perfusion agent control IRDye 700DX (700 nm channel). Observed fluorescence is
most stable in the broad beam fluorescence systems (Solaris and Pearl), while the Odyssey scanning system is more prone to large variations in
signal over time, likely due to high surface weighting and less tissue-volume averaging. Values reported as mean (standard deviation [SD]).
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highest absorption and scatter properties (1% intralipid, 2%
blood condition). These data indicate that the commonly
encountered tissues in sarcoma surgery, namely muscle, fat,
fascia, and nerve can be accurately represented in phantom
models, and therefore, such models could be utilized to further
investigate indirect fluorescence for sarcoma resection.
Large-scale surgical phantoms were made to study the effect
of ABY-029 inclusion concentration and TBR on our ability to
surgically excise a sarcoma tumor using indirect fluorescence
(Figure 4A-E). Using the gelatin well phantoms and the naive
mouse tissues as guidelines for normal connective tissue opti-
cal properties, the surgical phantoms were made using moder-
ate scatter and absorption conditions (1% intralipid and 1%
blood). We demonstrated that a surgeon, blinded to the location
of the inclusion, could excise the inclusion with a reasonable
margin (*1 cm) for all inclusion concentrations tested (Figure
4F) and with TBRs ranging from 10:1 to 3:1 (Figure 4G).
Surgical margins around the inclusion with TBRs of 2:1 and
1:1 were not achievable due to the lack of fluorescence
contrast; these ratios resulted in cuts into the inclusion and were
considered a failed experiment. Therefore, we can conclude
that a TBR of at least 3:1 is likely required to be able to
perform sarcoma resection using indirect fluorescence gui-
dance. Still, more extensive phantoms and sarcoma-bearing
mice will need to be tested to further validate the depth of
imaging, optimal ABY-029 dose, and timing from ABY-029
administration to surgery.
Conclusion
Fluorescence guidance has proven effective for enhancing the
accuracy of cancer surgery where the tumor is viewed directly
and removal of the normal surrounding tissue, such as in the
brain, may be harmful to the patient. However, many other
cancer types require wide local excision with the goal of neg-
ative margins for cure. In these cases, the use of fluorescence to
monitor tumor location and margin thickness is likely possible
but would require more complex accounting for marginal tissue
Figure 4. Surgical phantoms for assessing surgical resection margin utilizing a Solaris imager to display indirect fluorescence. Inclusion and
background were made with 10% (wt/vol) gelatin, 1% (vol/vol) blood, and 1% (vol/vol) intralipid, and the levels of ABY-029 were varied. A,
Photograph of the surface of the surgical phantom (11 cm diameter and 6 cm height). B, Fluorescence from the 16.4 cm3 fluorescent inclusion
overlaid on a white light photograph. The colored lines indicate cut lines as the boundary of the inclusion is gradually approached. The resulting
inclusion with *1 cm margins as a white light image (C) and fluorescence overlay (D). E, The inclusion was bisected and the margin distance
assessed manually using Fiji.48-50 F, The margin assessment of inclusions with varying concentrations of ABY-029 and nonfluorescent background.
G, The margin assessment with constant ABY-029 concentration in the inclusion (500 ng/mL), and varying ABY-029 concentration in the
background to achieve 10:1, 5:1, 3:1, 2:1, and 1:1 inclusion-to-background ratios.
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and tumor volume, optical characteristics, and excitatory signal
strength. Our preliminary investigation demonstrates that the
tissue-mimicking phantoms accurately simulate the optical
properties of naive mouse connective tissues with the use of
ABY-029. Furthermore, our naive mouse experiment suggests
that ABY-029 may be effective in distinguishing EGFR-
positive sarcoma tumors within their surrounding tissues after
intravascular clearance of the EGFR-targeted probe. Finally, a
TBR of 3:1 is likely the minimum ratio necessary for success-
ful excision of a tumor with clear margins. Near-infrared
fluorescence is a promising tool for indirect, subsurface visua-
lization of tumors requiring surgical resection by wide local
excision, and further investigation should continue to deline-
ate the properties of ABY-029 and other targeted probes in
naive and tumor tissues.
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